Abstract
Circulating tumour markers for breast cancer can be classified in different groups: mucins such as CA 15.3, CA 27.29 and CA 549, carcinoembryonic antigen (CEA), cytokeratins (TPA, TPs, Cyfra 21.1), enzymes (LDH), hormones and their subunits. All of them have been proposed over the years for the diagnosis and monitoring of breast cancer at different stages. It is well known that tumour marker tests lack in sensitivity at the earliest stage of cancer and also in specificity. False-negative results are rare in patients with advanced disease and metastases; on the contrary they are most frequent in the first stages. Besides this, false-positive results can be due to different nonmalignant conditions. At present CA 15.3 is the most widely used tumour marker in breast cancer patients. Its use follows the general concepts everywhere accepted for mucinic markers: the CA 15.3 test is not useful in screening and early diagnosis; it has an established role in the diagnosis of recurrences; it has an established role in therapy monitoring, alone or in association with other diagnostic tools; it is still under study as a predictor of response to therapy. Several international guidelines help physicians in using tumour markers giving practical recommendations for the appropriate interpretation of circulating tumour markers. CEA and cytokeratins markers are so far less specific than mucinic markers; therefore, they are sometimes tested for evaluating breast cancer patients.
The association of tumour marker tests with a diagnostic imaging modality such as FDG-PET today is of great interest, because sometimes the patients present with a tumour marker increase and do not show clinical symptoms or signs of cancer, or on the contrary some others subjects present with some doubtful symptoms or signs of cancer, and the association with a biochemical test for malignancy can be helpful to make the final diagnosis. FDG-PET is known as a metabolic imaging modality, that, contrary to radiological techniques, reveals cancer not on the basis of morphology like the radiological methods, but because of the uptake and/or processing of a radioactive tracer in cancer tissue. The visualization of cancer by PET depends on the viability and activity of the tumour, and this requirement is very close to the function of synthesis and secretion of tumour markers as products of cell metabolism. One can say that FDG-PET and tumour marker tests describe cancer activities in different ways, and their diagnostic added value takes advantage of this combination.
This chapter overviews the results of the association of FDG-PET with elevated or progressively increasing tumour markers. Tumour-marker-guided PET has demonstrated a diagnostic effectiveness in detecting cancer lesions with variable sensitivity, both at presentation (staging) and during the follow-up (discovery of relapses, metastases and re-staging). It is well known that tumour marker increase is a reliable signal of the presence of occult disease, and this suspicion can be explored by FDG-PET. For this reason some authors have proposed that whole body PET may become the method of choice for the assessment of asymptomatic patients with elevated tumour marker levels. The recent development of hybrid systems, allowing the concomitant examination of the patient by combining PET with CT, has increased the accuracy of diagnostic imaging, and several papers support the evidence that PET/CT is able to add incremental diagnostic confidence to PET and detects more lesions than CT or PET alone. A discussion is still open about the question if FDG-PET or PET/CT can substitute the entire battery of tests routinely used for staging breast cancer or detecting relapse in all breast cancer patients. At present, it is very difficult to draw a final conclusion, since one should consider the cost of the test, the non-complete availability of this examination in all clinical centres, and the problem of the limited sensitivity of PET in early stages, which is not able to rule out the microscopic metastases. There is still a need for further prospective clinical trials for evaluating the impact of this approach on patient management and survival, according to the different risk groups. However, in spite of several controversies in this field, there is no doubt that the association of tumour marker tests with PET or PET/CT seems to provide useful information, and this approach is indicated, mainly in the follow-up of patients at risk, in re-staging patients with symptoms and in evaluating the response to treatments.
The authors have written this paper on behalf of the Group of Immunometric Assays of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Adler LP, Bakale G (2001) Positron emission tomography imaging. In: Khalkali I, Maublant JC, Goldsmith SJ (eds) Nuclear oncology. Diagnosis and therapy. Lippincott Williams & Wilkins, Philadelphia 289–295
Agresti R, Crippa F, Gerali A et al (2004) Lymph node metastases detection by FDG-PET and sentinel node biopsy in breast cancer patients: comparison of these different approaches. ESSOI Congress
Aide N, Huchet V, Switsers O et al (2007) Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun 28:267–272
Avril N, Dose J, Janicke F et al (1996) Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 14:1848–1857
Avril N, Scheidhauer K, Kuhun W (2000) Breast cancer. In: Helmut J, Wieler R, Coleman E (eds) PET in clinical oncology. Springer, New York, 355–372
Bast RC, Ravdin P, Hayes DF et al (2001) American Society of Clinical Oncology Tumor Markers Expert Panel. J Clin Oncol 19:1865–1878
Basuyau JP, Blanc-Vincent MP, Bidart JM et al (2003) Summary report of the standards, options and recommendations for the use of serum tumour markers on breast cancer: 2000. Br J Cancer 89:32–34
Benchimol S. Fuks A, Jothy S, Beauchemin N, Shirota K, Stanner C (1989) Carcinoembryonic antigen, a human tumor marker, functions as a intercellular adhesion molecule. Cell 57:327–334
Bender H, Palmedo H, Biersack HJ (1998) Breast imaging with positron emission tomography. In: Taillefer R, Khalkhali I, Waxman AD, Biersack HJ (eds) Radionuclide imaging of the breast. Marcel Dekker, New York, 147–175
Berling B, Kolbinger F, Gruntert F et al (1990) Molecular cloning of a carcinoembryonic antigen (CEA)-gene family member expressed in leukocytes of chronic myeloid leukaemia patients and bone marrow. Cancer Res 50:6534–6539
Bombardieri E (1998) Tumor markers. In: Masson (ed) Handbook of medical oncology. Parigi, Barcellona, Messico, Milan, 145–159
Brem RF, Schoonians JM, Kieper DA et al (2002) High-resolution scintimammography: a pilot study. J Nucl Med 43:909–915
Chan DW, Beveridge RA, Muss H et al (1997) Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15:2322–2328
Cheung KL, Graves CRL, Robertson JFR (2000) Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26:91–102
Cody HS 3rd (2003) Sentinel lymph node biopsy for breast cancer: does anybody not need one? Ann Surg Oncol 10:1131–1132
Danforth DN Jr, Aloj L, Carrasquillo JA et al (2002) The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 75:135–146
Delbeke D, Martin WH (2004) Metabolic imaging with FDG: a primer. Cancer J 10:201–213
Dose J, Bleckmann S, Bachmann S et al (2002) Comparison of fluorodeoxyglucose positron emission tomography and conventional diagnosis procedures for the detection of distant metastases in breast cancer patients. Nucl Med Commun 23:857–864
Duffy MJ (2001) Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 34:347–352
Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345–351
Gil-Rendo A, Zorzona G, Garcia-Velloso MJ, Regueira FM, Beorlegui C, Cervera M (2006) Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93:707–712
Gion M, Barioli P, Mione R et al (1995) Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment. Forza Operativa Nazionale sul Carcinoma Mammario (FONCaM) Ann Oncol 6:31–35
Gion M, Boracchi P, Dittadi R et al (2002) Prognostic role of serum CA 15.3 in 362 node-negative breast cancer. An old player for a new game. Eur J Cancer 38:1181–1188
Gion M, Mione R, Bruscagni G (1993) Clinical use of tumor markers, current strategies for decision making. In: Ballesta A, Torre GC, Bombardieri E, Gion M, Molina R. Updating on tumor markers in tissues and in biological fluids. Minerva Medica, Torino, 179–202
Greco M, Crippa F, Agresti R et al (2001) Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 93:630–635
Hayes D, Sekine H, Ohao T et al (1985) Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 75:1671–1678
Hayes DF, Zurawski VR, Kufe DW (1986) Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 10:1542–1550
Kamel EM, Wyss MT, Fehr ML, von Schulthess GK, Goerres GW (2003) 18F-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 129:147–153
Kokko R, Holli K, Hakama M (2002) CA 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 38:1189–1193
Krag DN, Weaver DL, Alex JC et al (1993) Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma-probe. Surg Oncol 2:335–340
Liberman M, Sampalis F, Mulder DS et al (2003) Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature. Breast Cancer Res Treat 80:115–126
Liu CS, Shen YY, Lin CC, Yen RF, Kao CH (2002) Clinical impact of 18F-FDG PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 32:244–247
Lonneux M, Borbath I, Berlìere M, Kirkove C, Pauwels S (2000) The place of whole body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3:45–49
Lovrics PJ, Chen V, Coates G et al (2004) A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 11:846–853
Molina R, Barak V, van Dalen A et al (2005) Tumor markers in breast cancer-European Group on Tumour Markers recommendations. Tumour Biol 26:281–293
Molina R, Jo J, Filella X et al (1999) C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 19:2551–2555
Nagle R (1988) Intermediate filaments: a review of the basic biology. Am J Surg Pathol 12:4–16
Nakamura T, Kimura T, Umehara Y et al (2005) Periodic measurement of serum carcinombryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery. Surg Today 35:19–21
Ohta M, Tokuda Y, Suzuki Y et al (2001) Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22:875–879
Palmedo H, Bender H, Grunwald F et al (1997) Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxysobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 24:1138–1145
Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F et al (2001) Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2:229–234
Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Isreal O (2006) The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 107:2545–2551
Ravaioli A, Pasini G, Polselli A et al (2002) Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 72:53–60
Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332
Sampalis FS, Denis R, Picard D et al (2003) International prospective evaluation of scintimammography with 99mTcsestamibi. Am J Surg 185:544–549
Santiago JF, Gonen M, Yeung H, Macapinlac H, Larson S (2006) A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 50:61–67
Scheidhauer K, Walter C, Seeman MD (2004) FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging 31:S170–S179
Schillaci O, Manni C, Danieli R et al (2005) Tc-99m sestamibi scintimammography with a hybrid SPECT/CT imaging system. Eur J Nucl Med Mol Imaging 32:S128
Schillaci O, Scopinaro F, Spanu A et al (2002) Detection of axillary lymph node metastases in breast cancer with Tc-99m tetrofosmin scintimammography. Int J Oncol 20:483–487
Schirrmeister H, Kuhn T, Guhlmann A et al (2001) Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28:351–358
Schoder H, Gonen M (2007) Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 48: S4–S18
Seregni E, Bombardieri E (1999) Tumor markers in oncology. In: Aktolun C, Tauxe WN (eds) Nuclear oncology. Springer, Berlin Heidelberg New York, 415–432
Seregni E, Coli A, Mazzuca N (2004) Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 31:S15–S22
Shen YY, Su CT, Chen GJ, Chen YK, Liao AC, Tsai FS (2003) The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma 50:217–221
Siggelkow W, Rath W, Buell U, Zimny M (2004) FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging 31:S118–S124
Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W (2003) The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 23:1859–1867
Soletormos G, Nielsen D, Schioler V, Mouridsen H, Dombernowsky P (2004) Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 40:481–486
Steiner PM, Roop DR (1988) Molecular and cellular biology of intermediate filaments. Ann Rev Biochem 57:593–625
Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151–1159
Suarez M, Perez-Castejon MJ, Jimenez A, Domper M, Ruiz G, Montz R, Carreras JL (2002) Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46:113–121
Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL (2006) Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33:254–262
Trampal C, Maldonado A, Sancho Cuesta F et al (2000) Role of the positron emission tomography (PET) in suspected tumor recurrence when there are increased serum tumor markers. Rev Esp Med Nucl 19:279–287
Ugrinska A, Bombardieri E, Stokkel MP, Crippa F, Pauwels EK (2002) Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer. Q J Nucl Med 46:88–104
Valenzuela P, Mateos S, Tello E, Lopez-Bueno MJ, Garrido N, Gaspar MJ (2003) The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur J Gynaecol Oncol 24:60–62
Veronesi U, De Cicco C, Galimberti V et al (2007) A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18:473–478
Veronesi U., Paganelli G, Galimberti V et al (1997) Sentinelnode biopsy to avoid AD in breast cancer with clinically negative lymph nodes. Lancet 349:1864–1867
Voogd AC, Nielsen M, Peterse JL et al (2001) Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19:1688–1697
Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC (2002) Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128:325–328
Zangheri B, Messa C, Picchio M et al (2004) PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 31:S135–S142
Zornoza G, Garcia-Velloso MJ, Sola J, Regueira FM, Pina L, Beorlegui C (2004) 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 30:15–19
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bombardieri, E. et al. (2008). FDG-PET and Tumour Marker Tests for the Diagnosis of Breast Cancer. In: Bombardieri, E., Gianni, L., Bonadonna, G. (eds) Breast Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-36781-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-540-36781-9_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-36780-2
Online ISBN: 978-3-540-36781-9
eBook Packages: MedicineMedicine (R0)